VanEck Biotech ETF (NASDAQ:BBH) Short Interest Up 427.3% in February

Posted by Defense World Staff on Mar 13th, 2025

VanEck Biotech ETF (NASDAQ:BBH – Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 11,600 shares, a growth of 427.3% from the February 13th total of 2,200 shares. Based on an average daily volume of 10,500 shares, the short-interest ratio is currently 1.1 days. Currently, 0.5% of the company’s shares are short sold.

Institutional Trading of VanEck Biotech ETF

Several institutional investors and hedge funds have recently made changes to their positions in BBH. Farther Finance Advisors LLC purchased a new position in VanEck Biotech ETF during the fourth quarter valued at approximately $32,000. Truvestments Capital LLC bought a new stake in VanEck Biotech ETF during the 3rd quarter valued at $44,000. FSA Wealth Management LLC purchased a new position in shares of VanEck Biotech ETF in the 3rd quarter valued at $54,000. Coastline Trust Co bought a new position in shares of VanEck Biotech ETF in the 3rd quarter worth $59,000. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of VanEck Biotech ETF during the 4th quarter worth $81,000. 32.05% of the stock is currently owned by institutional investors.

VanEck Biotech ETF Stock Up 0.1 %

Shares of NASDAQ:BBH opened at $161.90 on Thursday. The business’s 50 day moving average is $162.42 and its 200 day moving average is $168.09. The stock has a market cap of $395.04 million, a P/E ratio of 30.97 and a beta of 0.85. VanEck Biotech ETF has a 52-week low of $151.35 and a 52-week high of $183.64.

VanEck Biotech ETF Announces Dividend

The company also recently declared a dividend, which was paid on Tuesday, December 24th. Stockholders of record on Monday, December 23rd were given a dividend of $1.2517 per share. The ex-dividend date was Monday, December 23rd.

About VanEck Biotech ETF

(Get Free Report)

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.